Matinas BioPharma Holdings, Inc. (MTNB) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
MTNB Revenue Growth
Revenue Breakdown (FY 2020)
MTNB's revenue distribution by segment and geography for fiscal year 2020
By Product/Segment
MTNB Revenue Analysis (2013–2024)
As of May 8, 2026, Matinas BioPharma Holdings, Inc. (MTNB) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, MTNB's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $3.2 million in 2022.
Revenue diversification analysis shows MTNB's business is primarily driven by CFF Research Grant Revenue (100%). With over half of revenue concentrated in CFF Research Grant Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ARQT (+95.3% YoY), NKTR (-43.9% YoY), and GILD (+3.5% YoY). Compare MTNB vs ARQT →
MTNB Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| MTNBCurrent | $0 | - | - | - | |
 ARQT | $376M | +95.3% | - | -3.3% | |
 NKTR | $55M | -43.9% | -18.4% | -236.8% | |
 GILD | $29.4B | +3.5% | +3.6% | 40.1% | |
 PTCT | $1.7B | -53.3% | +35.4% | 49.5% |
MTNB Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | -100.0% | $0 | - | $-24,593,000 | - |
| 2023 | $1.1M | -65.6% | $1.1M | 100.0% | $-23,766,000 | -2168.4% |
| 2022 | $3.2M | +9560.6% | $-13,490,000 | -423.1% | $-24,590,000 | -771.3% |
| 2021 | $33K | -79.2% | $-14,550,000 | -44090.9% | $-24,735,000 | -74954.5% |
| 2020 | $158K | +76.3% | $-14,200,585 | -8968.8% | $-24,206,552 | -15288.4% |
| 2019 | $90K | -25.0% | $-11,144,736 | -12409.0% | $-18,921,036 | -21067.4% |
| 2018 | $120K | -20.0% | $-6,667,724 | -5568.0% | $-14,646,545 | -12230.9% |
| 2017 | $150K | - | $-8,860,812 | -5919.6% | $-16,502,404 | -11024.6% |
| 2016 | $0 | -100.0% | $-52,644 | - | $-8,257,133 | - |
| 2015 | $194K | - | $-5,097,699 | -2621.0% | $-9,911,499 | -5096.0% |
See MTNB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MTNB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MTNB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMTNB — Frequently Asked Questions
Quick answers to the most common questions about buying MTNB stock.
Is MTNB's revenue growth accelerating or slowing?
MTNB TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is MTNB's long-term revenue growth rate?
Matinas BioPharma Holdings, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is MTNB's revenue distributed by segment?
MTNB reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.